We are live on ! Find out more
GILD icon

Gilead Sciences

1,630 hedge funds and large institutions have $97.1B invested in Gilead Sciences in 2016 Q1 according to their latest regulatory filings, with 119 funds opening new positions, 738 increasing their positions, 656 reducing their positions, and 99 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 99

13% more repeat investments, than reductions

Existing positions increased: 738 | Existing positions reduced: 656

0% more funds holding

Funds holding: 1,6281,630 (+2)

6% less call options, than puts

Call options by funds: $1.74B | Put options by funds: $1.84B

16% less capital invested

Capital invested by funds: $116B → $97.1B (-$19.2B)

17% less funds holding in top 10

Funds holding in top 10: 224187 (-37)

Holders
1,630
Holders Change
+2
Holders Change %
+0.12%
% of All Funds
43.42%
Holding in Top 10
187
Holding in Top 10 Change
-37
Holding in Top 10 Change %
-16.52%
% of All Funds
4.98%
New
119
Increased
738
Reduced
656
Closed
99
Calls
$1.74B
Puts
$1.84B
Net Calls
-$105M
Net Calls Change
+$506M
Name Holding Trade Value Shares
Change
Change in
Stake
SC
326
Scotia Capital
Ontario, Canada
$22.1M +$2.08M +23,056 +11%
AP
327
Atwood & Palmer
Missouri
$21.7M +$5.03M +55,826 +31%
PI
328
PineBridge Investments
New York
$21.7M -$3.92M -43,438 -16%
HPC
329
HM Payson & Co
Maine
$21.5M +$1.08M +11,932 +5%
BG
330
Bellevue Group
Switzerland
$21.4M +$21M +233,300 New
ZIG
331
Zurich Insurance Group
Switzerland
$21.4M -$1.03M -11,386 -5%
DL
332
Delta Lloyd
Netherlands
$21.4M -$2.79M -30,964 -12%
DnB Asset Management
333
DnB Asset Management
Norway
$21.2M +$10.4M +115,300 +99%
DILH
334
Dai-ichi Life Holdings
Japan
$21.2M +$332K +3,685 +2%
ELC
335
Edgar Lomax Company
Virginia
$21.1M +$11M +122,250 +113%
CFB
336
Cullen/Frost Bankers
Texas
$21.1M -$309K -3,430 -1%
CM
337
CS McKee
Pennsylvania
$21.1M -$2.7M -29,900 -12%
EAM
338
Edge Asset Management
Washington
$21M +$2.57M +28,483 +14%
RMDI
339
R.M. Davis Inc
Maine
$20.8M +$2.01M +22,270 +11%
GCM
340
Gabalex Capital Management
New York
$20.7M +$6.76M +75,000 +50%
CIBC Private Wealth Group
341
CIBC Private Wealth Group
Georgia
$20.5M +$3.7M +41,023 +22%
Daiwa Securities Group
342
Daiwa Securities Group
Japan
$20.5M +$4.98M +55,177 +33%
NLGIA
343
Nippon Life Global Investors Americas
New York
$20.5M -$452K -5,010 -2%
UCFA
344
United Capital Financial Advisors
Texas
$20.4M +$1.05M +11,644 +6%
ADEF
345
Adams Diversified Equity Fund
Maryland
$20.3M -$1.32M -14,600 -6%
Public Sector Pension Investment Board (PSP Investments)
346
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$20.3M -$13.2M -146,800 -40%
ZIC
347
ZWJ Investment Counsel
Georgia
$20.2M +$348K +3,857 +2%
NPPM
348
North Point Portfolio Managers
Ohio
$20M -$331K -3,665 -2%
MC
349
Muhlenkamp & Co
Pennsylvania
$20M +$1.35K +15 +0%
FQ
350
First Quadrant
California
$20M -$1.64M -18,176 -8%

GILD Hedge Fund Activity: Q1 2016 in Review

1,630 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2016, worth a combined $97.1B — down 16% from $116B a quarter earlier.

Buyers outnumbered sellers: 119 funds opened new GILD positions and 99 closed out — a net gain of 20 holders — while 738 added to existing stakes and 656 trimmed.

The largest buyer was Royal London Asset Management, adding an estimated $2.73B. The largest seller was Capital Research Global Investors, cutting an estimated $1.99B.

  • 1,630 institutional investors held Gilead Sciences (GILD) as of Q1 2016, up from 1,628 in Q4 2015.
  • Funds reported $97.1B of Gilead Sciences stock for Q1 2016, down 16% quarter-over-quarter.
  • 119 funds opened new Gilead Sciences positions in Q1 2016 and 99 closed out, a net change of +20 holders.
  • The largest Gilead Sciences buyer in Q1 2016 was Royal London Asset Management, an estimated $2.73B added.
  • The largest Gilead Sciences seller in Q1 2016 was Capital Research Global Investors, an estimated $1.99B sold.

Based on aggregated 13F filings for Q1 2016.